Effects of concentrated Edaravone and Dexborneol Concentrated Solution for Injection on inflammatory factors in patients with amyotrophic lateral sclerosis

开始日期2025-04-11

申办/合作机构

宜昌市中心人民医院

NCT06757504

/ Recruiting临床2期

A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-controlled Phase II Trial of TTYP01 Tablets in Adolescents and Children With Autism Spectrum Disorders

This is a multi-center, randomized, double-blind, multiple dose levels, parallal group, placebo-controlled study, to evaluate the safety, PK profiles and preliminary efficacy of TTYP01 tablets in adolescents and children with ASD.

开始日期2025-01-07

申办/合作机构

上海澳宗生物科技有限公司

ChiCTR2400094236

/ Suspended临床3期IIT

A clinical study on the treatment of cerebral small vessel disease-related cognitive dysfunction with edaravone sublingual tablets

开始日期2024-12-30

申办/合作机构-

100 项与依达拉奉相关的临床结果

登录后查看更多信息

100 项与依达拉奉相关的转化医学

登录后查看更多信息

100 项与依达拉奉相关的专利（医药）

登录后查看更多信息

6,130

项与依达拉奉相关的文献（医药）

2025-12-01·MOLECULAR BIOLOGY REPORTS

Edaravone reduces brain injury in hepatic encephalopathy by upregulation of Nrf2/HO-1 and inhibition of NF-κB, iNOS/NO and inflammatory cytokines

Article

作者: Amirshahrokhi, Keyvan ; Imani, Mahsa

BACKGROUND:

Brain damage is the most important complication in patients with hepatic encephalopathy (HE). Oxidative stress and inflammation are essential factors in the progression of brain injury caused by HE. The aim of this study was to investigate the potential therapeutic effect of edaravone and its underlying mechanisms against brain injury associated with HE in mice.

METHODS AND RESULTS:

HE was induced by the injection of thioacetamide (200 mg/kg) for 2 days and then mice treated with edaravone (10 or 20 mg/kg/day, ip) for four consecutive days. The brain tissues were dissected for histopathological, biochemical, ELISA, RT-qPCR and immunofluorescence analysis. The results showed that edaravone improved the locomotor function and ameliorated brain histopathological changes in mice with HE. Edaravone inhibited oxidative stress markers by increasing the levels of glutathione, catalase, superoxide dismutase, glutathione reductase and the upregulation of nuclear erythroid 2-related factor (Nrf2)/HO-1 pathway in the brain tissue. Administration of edaravone significantly decreased the expression of p-NF-κB and iNOS. Edaravone treatment reduced the levels of NO, MPO and MMP-9 in the brain of mice. Additionally, the brain levels and expressions of inflammatory cytokines IL-1β, IL-6, TNF-α and IFN-γ were downregulated in mice treated with edaravone.

CONCLUSIONS:

These results suggest that edaravone exerts significant neuroprotection by modulating of inflammatory and oxidative responses in HE and may serve as a promising agent for the treatment of brain injury associated with HE.

2025-11-01·Neural Regeneration Research

Biochemical dissection of STAT3 signaling in amyotrophic lateral sclerosis

Article

作者: Apolloni, Savina ; D’Ambrosi, Nadia

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the loss of upper and lower motor neurons, clin. marked by muscle atrophy and weakness.Although the clin. course is highly variable, the average time from the onset of symptoms to the need for respiratory support or death is 3-5 years.ALS is the most prevalent motor neuron disease in adults, occurring at a rate of 2 per 100,000 individuals and affecting 5.4 per 100,000 individuals overall.

2025-08-01·Neural Regeneration Research

Carboplatin restores neuronal toxicity in FUS-linked amyotrophic lateral sclerosis

Article

作者: Kim, Kiyoung

Amyotrophic lateral sclerosis (ALS), also known as Lou Geh rig′s disease, is a progressive neurodegenerative disorder that affects motor neurons in the brain and spinal cord.This leads to muscle weakness, paralysis, and ultimately, respiratory failure (Cha and Kim, 2022).There is currently no cure for ALS.Riluzole, a primary treatment for ALS, has been shown to extend survival by an average of three months.Another drug, Edaravone, has been approved for ALS treatment in some countries; however, its efficacy remains controversial (Cha and Kim, 2022).These drugs target various mechanisms that contribute to neuronal degeneration in ALS, including glutamate excitotoxicity and oxidative stress.Although several studies have attempted to elucidate the underlying mechanisms, there remains an unmet need for more effective therapies to halt or reverse disease progression.Therefore, novel therapeutic strategies are urgently needed.

450

项与依达拉奉相关的新闻（医药）

2025-03-25

·PRNewswire

Mitsubishi Tanabe Pharma America Announces Publication of Preclinical Research on the Role of Edaravone in Mitigating TDP-43 Mislocalization in ALS

Results from this analysis were published in Free Radical Biology and Medicine JERSEY CITY, N.J., March 25, 2025 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of new preclinical research in Free Radical Biology and Medicine, highlighting the role of edaravone in mitigating TDP-43 mislocalization, a hallmark feature observed in more than 97% of sporadic amyotrophic lateral sclerosis (ALS) cases. The study, conducted using induced pluripotent stem cell (iPSC)-derived motor neurons from a single patient with ALS, demonstrated that edaravone significantly reduced the abnormal cytoplasmic accumulation of TDP-43, restoring its nuclear localization. This mislocalization is a key driver of neuronal dysfunction and degeneration in ALS, and suggests that edaravone may offer a varied therapeutic approach for ALS by targeting oxidative stress and TDP-43 mislocalization through distinct molecular pathways. "These findings help build upon our understanding of edaravone's potential effects in ALS," said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at MTPA. "By modulating TDP-43 pathology and engaging molecular pathways linked to neurodegeneration, edaravone may play a broader role in ALS management than previously understood and should continue to be studied." "This study provides preclinical evidence that edaravone's MOA in ALS extends beyond its known antioxidant properties," said Satsuki Mikuriya, Research Scientist at MTPA and lead author of the study. Key findings from the study include: In ALS patient-derived neurons from a patient with ALS harboring a TDP-43 mutation, edaravone significantly reduced the cytoplasmic accumulation of TDP-43, restoring its nuclear localization. Unlike vitamin C, edaravone preserved neurite structures and reduced neurotoxicity, supporting a unique mechanism of action. Edaravone treatment induced significant changes in gene expression as early as six hours post-treatment, with key pathways related to protein degradation and neuroprotection. Edaravone's effects were associated with modulation of the SIRT1-XBP1 pathway, a key regulator of cellular stress responses, suggesting a broader role in ALS neuroprotection. This preclinical study was conducted using iPSC-derived motor neurons from a single ALS patient with a specific TDP-43 mutation (A382T) in an in vitro setting. Additional research in animal models and clinical settings (including those with other ALS-related mutations and patients with sporadic ALS) is needed to confirm these findings. Additionally, recent research has highlighted not only the toxic gain of function caused by TDP-43 aggregation but also the pathological sequences of TDP-43 loss of function due to its nuclear depletion. Further studies are required to explore how edaravone influences the loss of TDP-43 function. While the study provides important new insights into edaravone's potential role in ALS treatment, further research is needed to confirm its effects in larger, more diverse ALS models and to explore its long-term impact on disease progression. This analysis was funded and conducted by MTPA. Additional results can be found in the publication, titled, "Edaravone mitigates TDP-43 mislocalization in human amyotrophic lateral sclerosis neurons with potential implication of the SIRT1-XBP1 pathway." About Mitsubishi Tanabe Pharma America, Inc. Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). It was established by MTPC to develop and advance our pipeline as well as commercialize approved pharmaceutical products in North America. For more information, please visit or follow us on X (formerly Twitter), Facebook and LinkedIn. About Mitsubishi Tanabe Pharma Corporation Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan's pharmaceutical industry. MTPC sets the MISSION of "Creating hope for all facing illness". To that end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney, and cancer. MTPC is focusing on "precision medicine" to provide drugs with high treatment satisfaction by identifying patient populations with high potential for efficacy and safety. In addition, MTPC is working to develop "around the pill solutions" to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis. For more information, go to Media inquiries: [email protected] SOURCE Mitsubishi Tanabe Pharma America WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-03-14

·求实药社

生存期延长15月！渐冻症新药临床研究结果积极！

来源：药讯随说 3月12日（当地时间），Clene Inc及其子公司Clene Nanomedicine宣布其纳米药物CNM-Au8在肌萎缩侧索硬化（ALS，渐冻症）临床研究（HEALEY ALS平台研究）患者的交叉方案长期生存事后分析结果积极。 HEALEY ALS平台研究（主研究：NCT04297683）为一项评估多种方案在稳定背景治疗（利鲁唑和/或依达拉奉）ALS患者中有效性、安全性、PK和PD的全球多中心、随机、双盲、安慰剂对照的确证性III期临床研究。研究主要终点为生存改善，次要有效性终点为ALS临床恶化事件延迟时间。平台试验包括7个方案，分别为：Zilucoplan（泽勒普肽，方案A：NCT04436497）、Verdiperstat（方案B：NCT04436510）、CNM-Au8（方案C：NCT04414345）、Pridopidine（普利多匹定，方案D：NCT04615923）、Trehalose（海藻糖，方案E：NCT05136885）、ABBV-CLS -7262(方案F：NCT05740813）、DNL343（方案G：NCT05842941）。方案A：患者3：1随机接受24周活性治疗（每天一次皮下注射Zilucoplan，0.3mg/kg）或匹配安慰剂治疗。方案C：患者2：1随机接受108周活性治疗（30mg）或匹配安慰剂治疗. 本次公布结果如下： 1、全分析集（FAS）：中位生存：CNM-Au8 30mg组 (方案C,n=59)和方案A对照组（n=162）中位生存天数分别为951天、753天，增加198天（6.5月）；限制平均生存时间（RMST）：协变量校正RMST增加124天（4.1月）（95%CI：3-245；p=0.045）； 2、中-重度ALS患者增强获益：基线血清NfL（神经丝轻链蛋白）≥33pg/ml和TRICALS风险得分-6.5至-2.5间人群中，方案C（n=51）较方案A（n=120）中位生存时间从589天提高至951天，增加11.9月；死亡风险降低44%（Cox HR=0.556;95%CI:0.367-0.842;p=0.006),RMST增加197天（6.5月，95%CI：65-329；p=0.004）； 3、符合入选标准集【血清NfL（神经丝轻链蛋白）≥33pg/ml，TRICALS风险得分-6.5至-2.5间，基线慢肺活量≥60%，发病时间≤36月】方案C（n=40）较方案A（n=94）中位生存时间从628天提高至1079天，增加14.8月（451天）；死亡风险降低49%（Cox HR=0.514;95%CI:0.319-0.83;p=0.006),RMST提高215天（7.1月，95%CI：70-360；p=0.004） CNM-Au8是一种具有催化活性、表面清洁、浓缩的金元素多面纳米晶体的水悬浮液。通过提供和/或接收电子驱动大脑中关键的细胞能量生成反应，通过增加神经元和胶质细胞对疾病相关应激的耐受性，使神经修复和髓鞘再生成为可能，并减少有害的反应性分子。免责声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担, 关于对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部。联系我们 SIT 2025 展位火热预定中！扫码立即咨询电话：13816031174 （同微信）赞助形式包括但不仅限于演讲席位、会场展位、会刊彩页、晚宴赞助、会议用品宣传等。点击此处“阅读全文”咨询更多精彩！

临床结果临床3期

2025-03-12

·PRNewswire

Mitsubishi Tanabe Pharma America to Showcase New Research Findings in ALS at 2025 MDA Clinical and Scientific Conference

JERSEY CITY, N.J., March 12, 2025 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of eleven abstracts covering research in amyotrophic lateral sclerosis (ALS) at the 2025 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference being held in Dallas, Texas, March 16-19. "We are looking forward to presenting our latest ALS research, including an innovative study exploring how clinical algorithms may aid in the diagnosis of ALS," said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs, MTPA. "We remain dedicated to advancing ALS research and fostering scientific dialogue at medical meetings and congresses on our mission to provide meaningful treatment options and help improve the lives of those affected by this disease." RADICAVA ORS® (edaravone) Studies: Final efficacy and safety results from two multi-center, Phase 3b, double-blind, parallel group studies will be presented, including a comparison of daily dosing of RADICAVA ORS® (edaravone) with the FDA-approved on/off regimen, assessed at 48 weeks (MT-1186-A02) and its extension study (MT-1186-A04). Safety data from a Phase 3 open-label safety extension study for up to 96 weeks (MT-1196-A03) will also be shared. An additional presentation will examine the long-term function and survival of patients treated with RADICAVA ORS using data from propensity score-matched patients in the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database. Phase 3b Study MT-1186-A02 to Investigate the Superiority of Daily Dosing vs the FDA-approved On/Off Regimen of Oral Edaravone in Patients with ALS (Alejandro Salah, M.D., Ph.D., MBA, MHA; MTPA) Poster Session: 6:00 p.m. – 8:00 p.m. CT, March 16 – March 18, 2025 Phase 3, Open-Label, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Patients with ALS (MT-1186-A03) (Stephen Apple, M.D.; MTPA) Poster Session: 6:00 p.m. – 8:00 p.m. CT, March 16 – March 18, 2025 Phase 3b Study MT-1186-A04 Extension Study to Evaluate the Continued Efficacy and Safety of Radicava ORS® (Oral Edaravone) for up to an Additional 48-Weeks in Patients With Amyotrophic Lateral Sclerosis (Alejandro Salah, M.D., Ph.D., MBA, MHA; MTPA) Poster Session: 6:00 p.m. – 8:00 p.m. CT, March 16 – March 18, 2025 Analysis of Long-term Function and Survival of Radicava ORS® (Oral Edaravone)-Treated Patients With Amyotrophic Lateral Sclerosis vs Propensity Score–Matched PRO-ACT Historical Controls (Stephen Apple, M.D.; MTPA) Poster Session: 6:00 p.m. – 8:00 p.m. CT, March 16 – March 18, 2025 Real World Data: Presentations will highlight a clinical algorithm designed to analyze electronic medical record (EMR) data of neurologists, which aims to reduce delays in ALS diagnosis and treatment. Findings from the ALS/Motor Neuron Disease National History Consortium database will provide insights into the survival, treatment patterns and clinical outcomes of patients treated for ALS. In addition, studies examining referral patterns for ALS diagnosis, as well as demographics and healthcare resource utilization (HCRU) trends across specialty and non-specialty treatment centers, will be shared. Further, two studies will explore point-of-care quality classifications and at-home telespirometry assessments, evaluating forced vital capacity as well as erect and supine slow vital capacity in individuals with ALS. Smartphone Application-Mediated Supervised At-Home Telespirometry Erect and Supine Slow Vital Capacity (eSVC/sSVC) Measurements in Subjects With Amyotrophic Lateral Sclerosis Identify Statistically Significant Differences in eSVC/sSVC Decline as Function of Non-Invasive Ventilation Treatment Status [NCT05106569] (Stephen Apple, M.D.; MTPA) Poster Session: 6:00 p.m. – 8:00 p.m. CT, March 16 – March 18, 2025 Smartphone Application–Mediated, Supervised, At-Home Telespirometry Vital Capacity Measurements in Amyotrophic Lateral Sclerosis: Comparison of American Thoracic Society/European Respiratory Society Point-of-Care Quality Assessment Algorithms Implemented for Slow Vital Capacity and Forced Vital Capacity [NCT05106569] (Stephen Apple, M.D.; MTPA) Poster Session: 6:00 p.m. – 8:00 p.m. CT, March 16 – March 18, 2025 Referral Patterns for Patients With Amyotrophic Lateral Sclerosis Enrolled in a US-Based Administrative Claims Database (Malgorzata Ciepielewska, M.S.; MTPA) Poster Session: 6:00 p.m. – 8:00 p.m. CT, March 16 – March 18, 2025 Investigating Application of a Clinical Algorithm on Real-World Electronic Medical Record Data for Earlier Detection of Amyotrophic Lateral Sclerosis (Dung Pham, Ph.D.; MTP-CA) Poster Session: 6:00 p.m. – 8:00 p.m. CT, March 16 – March 18, 2025 Treatment of Amyotrophic Lateral Sclerosis in General and Specialist US Healthcare Settings: Results From a Real-World Survey (Malgorzata Ciepielewska, M.S.; MTPA) Poster Session: 6:00 p.m. – 8:00 p.m. CT, March 16 – March 18, 2025 Survival Benefits and Treatment Patterns of Edaravone–Treated People With Amyotrophic Lateral Sclerosis in the ALS/MND Natural History Consortium (Malgorzata Ciepielewska, M.S.; MTPA) Poster Session: 6:00 p.m. – 8:00 p.m. CT, March 16 – March 18, 2025 Preclinical Data: Data from a preclinical study examining the effects of edaravone on spinal motor neurons derived from an ALS patient carrying the A382T mutation in TDP-43, as analyzed through a comprehensive transcriptomic approach, will be presented. Transcriptomic Signature Induced by Edaravone in Motor Neurons From an ALS Patient With a TDP-43 Mutation (Alejandro Salah, M.D., Ph.D., MBA, MHA; MTPA) Poster Session: 6:00 p.m. – 8:00 p.m. CT, March 16 – March 18, 2025 About RADICAVA® (edaravone) and RADICAVA ORS® (edaravone) The U.S. Food and Drug Administration (FDA) approved RADICAVA® (edaravone) on May 5, 2017, and the oral formulation RADICAVA ORS® (edaravone) on May 12, 2022, for the treatment of amyotrophic lateral sclerosis (ALS). In 2024, the FDA recognized RADICAVA ORS with Orphan Drug Exclusivity based on the major contribution to patient care of the innovative oral formulation. RADICAVA is administered in 28-day cycles by intravenous (IV) infusion. It takes 60 minutes to receive each 60 mg dose. For the initial cycle, the treatment is infused daily for 14 consecutive days, followed by a two-week drug-free period. All cycles thereafter are infused daily for 10 days within a 14-day period, followed by a two-week drug-free period. RADICAVA ORS is taken daily for 14 consecutive days followed by a 14-day drug-free period for the initial treatment cycle. For subsequent treatment cycles, RADICAVA ORS is taken for 10 days within a 14-day period followed by a 14-day drug-free period. RADICAVA ORS should be taken in the morning after overnight fasting. Patients should not eat or drink (except water) within one hour after taking RADICAVA ORS.1 Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc. (MTPA). The MTPC group companies began researching ALS in 2001 through an iterative clinical platform over a 13-year period. In 2015, edaravone was approved as RADICUT® for the treatment of ALS in Japan and South Korea. Marketing authorizations were subsequently granted in Canada (October 2018), Switzerland (January 2019), Indonesia (July 2020), Thailand (April 2021), Malaysia (December 2021) and Brazil (February 2024). Marketing authorization for RADICAVA® Oral Suspension was granted in Canada (November 2022) and Switzerland (May 2023), and RADICUT® Oral Suspension 2.1% was granted regulatory approval in Japan in December 2022. To date, in the U.S., RADICAVA and RADICAVA ORS have been used to treat over 16,000 people with ALS, with over 2.0-million days of therapy, and have been prescribed by over 2,400 HCPs.2-4 IMPORTANT SAFETY INFORMATION Hypersensitivity Reactions RADICAVA (edaravone) and RADICAVA ORS (edaravone) are contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred with RADICAVA. Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA or RADICAVA ORS, treat per standard of care, and monitor until the condition resolves. Sulfite Allergic Reactions RADICAVA and RADICAVA ORS contain sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people. Adverse Reactions The most common adverse reactions (≥10%) reported in RADICAVA-treated patients were contusion (15%), gait disturbance (13%), and headache (10%). In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS. Pregnancy Based on animal data, RADICAVA and RADICAVA ORS may cause fetal harm. To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or . INDICATION RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS). For more information, including full Prescribing Information, please visit . About Mitsubishi Tanabe Pharma America, Inc. Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). It was established by MTPC to develop and advance our pipeline as well as commercialize approved pharmaceutical products in North America. For more information, please visit or follow us on X (formerly Twitter), Facebook and LinkedIn. About Mitsubishi Tanabe Pharma Corporation Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan's pharmaceutical industry. MTPC sets the MISSION of "Creating hope for all facing illness". To that end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney, and cancer. MTPC is focusing on "precision medicine" to provide drugs with high treatment satisfaction by identifying patient populations with high potential for efficacy and safety. In addition, MTPC is working to develop "around the pill solutions" to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis. For more information, go to Media inquiries: [email protected] 1 RADICAVA and RADICAVA ORS Prescribing Information. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.; 2022. 2 Data on file. Mitsubishi Tanabe Pharma America, Inc. 3 Data on file. Mitsubishi Tanabe Pharma America, Inc. 4 Data on file. Mitsubishi Tanabe Pharma America, Inc. SOURCE Mitsubishi Tanabe Pharma America WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期上市批准孤儿药

100 项与依达拉奉相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01552	依达拉奉	N07XX14	DB12243

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肌萎缩侧索硬化	日本	Mitsubishi Tanabe Pharma Corp.	2015-06-26
脑梗塞	日本	Mitsubishi Tanabe Pharma Corp.	2015-06-26
急性缺血性卒中	中国	先声药业有限公司	2003-12-31

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
雄激素不敏感综合征	临床3期	中国	上海澳宗生物科技有限公司	2023-04-25
青少年肌萎缩性侧索硬化症2	临床3期	日本	Mitsubishi Tanabe Pharma Corp.	2011-12-01
阿尔茨海默症	临床3期	荷兰	Treeway BV	-
自闭症谱系障碍	临床2期	中国	上海澳宗生物科技有限公司	2024-12-24
自闭症	临床2期	中国	上海澳宗生物科技有限公司	-
肝损伤	临床1期	日本	Mitsubishi Tanabe Pharma Corp.	2016-11-16
慢性肾病	临床1期	日本	Mitsubishi Tanabe Pharma Corp.	2016-10-27
视网膜变性疾病	临床前	-	-	2004-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04569084 (CTgov)	临床3期	肌萎缩侧索硬化	384	Edaravone (Edaravone 105 mg (Once Daily))	繭艱積網鹹顧夢蓋廠製(齋範範餘簾壓壓廠獵糧) = 繭願築鏇齋製憲淵遞襯網簾窪憲艱鹽觸鏇積獵 (淵齋簾範衊網襯鹹觸繭, 壓遞顧獵構網構構餘鑰 ~ 蓋鏇築夢構積鏇鬱膚淵) 更多	-	2025-03-27
				Edaravone (Edaravone 105mg (2 Weeks On/Off ))	繭艱積網鹹顧夢蓋廠製(齋範範餘簾壓壓廠獵糧) = 簾衊積蓋鏇淵壓築齋積網簾窪憲艱鹽觸鏇積獵 (淵齋簾範衊網襯鹹觸繭, 艱鬱糧鹽遞憲鏇選餘糧 ~ 網鹹醖衊艱遞遞蓋膚餘) 更多
NCT05178810 (ADOREXT \| ADORE, CTgov)	临床3期	肌萎缩侧索硬化	313	FAB122 (FAB122)	鑰觸獵鏇積簾艱齋糧襯(鑰顧夢顧齋網鏇餘鬱顧) = 鬱襯觸壓鏇壓窪窪餘鑰艱繭繭衊鹹窪積築簾憲 (蓋遞鏇壓選壓築觸遞築, 7.9) 更多	-	2025-03-25
				Placebo (Placebo)	鑰觸獵鏇積簾艱齋糧襯(鑰顧夢顧齋網鏇餘鬱顧) = 糧網製觸顧艱鏇製鏇構艱繭繭衊鹹窪積築簾憲 (蓋遞鏇壓選壓築觸遞築, 8.4) 更多
NCT05866926 (ADOREXT, CTgov)	临床3期	肌萎缩侧索硬化	201	FAB122 (FAB122)	鹹構壓鏇範壓遞艱鏇獵 = 醖觸壓顧鹹淵艱鏇壓醖廠鑰範顧餘範遞蓋憲憲 (憲簾選鹹繭鏇窪願製獵, 襯築襯襯簾齋淵糧窪膚 ~ 鬱鏇鬱遞壓遞鬱淵壓膚) 更多	-	2025-03-25
				FAB122 (Placebo)	鹹構壓鏇範壓遞艱鏇獵 = 積繭鹽鏇廠積獵廠壓顧廠鑰範顧餘範遞蓋憲憲 (憲簾選鹹繭鏇窪願製獵, 窪壓憲襯餘襯壓構膚壓 ~ 鹹築築鬱淵願獵繭網憲) 更多
NCT05568615 (CTgov)	临床3期	肌萎缩侧索硬化	15	MT-1186	構憲夢遞鬱築遞選構廠 = 願築範憲餘遞鏇築襯憲壓淵艱餘網選鬱衊構廠 (餘選膚廠選壓齋築衊築, 廠觸淵鑰鑰積網觸鬱鏇 ~ 製夢繭積選憲觸壓鏇鹽) 更多	-	2025-03-25
NCT03346538 (CTgov)	临床2期	急性缺血性卒中	17	Approved dosing regimen placebo+Continuous infusion high-dose MCI-186 (Continuous Infusion High-dose Group (Group H))	遞範鹹構築積壓繭夢醖 = 餘淵願築鏇廠醖壓鑰鹹襯蓋憲夢範構膚糧鏇簾 (顧網膚鬱觸繭夢襯鏇構, 願網齋繭願鏇鏇顧選顧 ~ 壓廠鬱願鹹範鑰觸築蓋) 更多	-	2025-03-25
				Approved dosing regimen placebo+Continuous infusion low-dose MCI-186 (Continuous Infusion Low-dose Group (Group L))	遞範鹹構築積壓繭夢醖 = 醖獵衊衊夢繭觸製築繭襯蓋憲夢範構膚糧鏇簾 (顧網膚鬱觸繭夢襯鏇構, 糧鑰壓願鹽鏇襯衊網簾 ~ 糧顧鏇淵窪選夢鹽鬱鏇) 更多
NCT04577404 (MT-1186-A03, CTgov)	临床3期	肌萎缩侧索硬化	124	MT-1186	淵鏇獵鑰衊製繭鬱淵蓋 = 蓋餘艱膚鏇廠齋製築範鑰獵構鹹網製壓願餘網 (壓淵夢鏇糧餘壓鹹製憲, 廠醖鑰窪積壓鑰鬱繭鹹 ~ 夢積膚糧構襯觸鏇遞蓋) 更多	-	2024-08-28
NCT04577404 (MT-1186-A03, Biospace) 人工标引	临床3期	肌萎缩侧索硬化	-	RADICAVA ORS	鏇糧簾繭糧鹽壓醖選窪(淵鹹夢糧艱淵積鏇積醖) = fall, muscular weakness, dyspnea, constipation, and dysphagia. 艱選衊廠餘築壓餘襯膚 (衊簾築繭觸廠顧繭膚艱 )	积极	2024-06-17
AAN2024	N/A	肌萎缩侧索硬化	231	IV edaravone to oral edaravone	願鹹築範餘鏇艱製蓋夢(獵鬱網選襯齋鏇鑰築齋) = 糧顧構醖壓觸淵鹹蓋餘積壓襯醖構淵蓋夢積網 (選鑰艱窪築簾醖顧艱鏇 ) 更多	积极	2024-04-09
				Oral edaravone-naïve	願鹹築範餘鏇艱製蓋夢(獵鬱網選襯齋鏇鑰築齋) = 衊醖鬱淵鏇觸蓋範夢構積壓襯醖構淵蓋夢積網 (選鑰艱窪築簾醖顧艱鏇 ) 更多
AAN2024	N/A	肌萎缩侧索硬化	-	Edaravone-naive patients	夢獵鹹鬱夢膚齋繭餘淵(鏇襯艱遞獵觸構鑰鏇顧) = 餘襯襯鬱範廠繭積壓憲選鹹製艱鏇艱構鹽襯獵 (醖鹹獵遞鹽餘範憲膚繭 )	-	2024-04-09
				Edaravone-experienced patients	夢獵鹹鬱夢膚齋繭餘淵(鏇襯艱遞獵觸構鑰鏇顧) = 蓋糧繭鬱範範範醖艱鑰選鹹製艱鏇艱構鹽襯獵 (醖鹹獵遞鹽餘範憲膚繭 )
MDA2024	N/A	肌萎缩侧索硬化	-	Edaravone-naïve patients	願觸遞網築製鹽鹹鹹網(鏇簾壓鹽簾獵遞襯獵憲) = 製糧襯憲憲顧獵壓鬱夢構遞構廠製觸獵鏇膚獵 (願構襯齋壓夢鹹齋願獵 )	-	2024-03-03
				Edaravone-experienced patients	願觸遞網築製鹽鹹鹹網(鏇簾壓鹽簾獵遞襯獵憲) = 製鹹簾壓製鹹憲醖築鏇構遞構廠製觸獵鏇膚獵 (願構襯齋壓夢鹹齋願獵 )